Plain-English translation of NCT06759753 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called , which is derived from stem cell proteins, to see if it can help people recover better after an acute ischemic stroke. Researchers will compare two different doses of against a placebo (a dummy treatment) to determine the safest and most effective dose. All participants will also receive a standard supportive medication called Ginkgo Ester to help with recovery.
While doctors have made progress in treating acute stroke, most treatments focus on preventing the initial damage rather than helping the brain heal afterward. This trial exists to find out if this new treatment can reduce long-term disability and improve how well people recover their brain function after a stroke.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive the study medication (either or placebo) as an intravenous infusion once daily for about two weeks, plus oral Ginkgo pills three times daily for three months. You would need to visit the hospital regularly for about 90 days for check-ups, blood tests, and brain scans to monitor your recovery and ensure the treatment is safe. The researchers will track your neurological recovery and ability to perform daily activities throughout this period.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
China